Cargando…
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
There is evidence that predisposition to cancer has a genetic component. Genetic models have suggested that there is at least one highly penetrant gene predisposing to this disease. The oncogene MXI1 on chromosome band 10q24-25 is mutated in a proportion of prostate tumours and loss of heterozygosit...
Autores principales: | Edwards, S. M., Dearnaley, D. P., Ardern-Jones, A., Hamoudi, R. A., Easton, D. F., Ford, D., Shearer, R., Dowe, A., Eeles, R. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228090/ https://www.ncbi.nlm.nih.gov/pubmed/9376279 |
Ejemplares similares
-
Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.
por: Dunsmuir, W. D., et al.
Publicado: (1998) -
ATM polymorphisms as risk factors for prostate cancer development
por: Angèle, S, et al.
Publicado: (2004) -
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010) -
Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012) -
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease
por: Meitz, J C, et al.
Publicado: (2002)